Pulmonology

Breast Cancer, Metastatic

Questions discussed in this category

Would you give T-DXd to patients with resolved drug-induced ILD from other agents such as prior chemo/targeted therapy/immunotherapy?

2 Answers available

How do you monitor for pulmonary toxicity for patients on trastuzumab deruxtecan?

Would you obtain baseline PFT on all patients or only selected high risk patients? Would you repeat PFTs regularly or only if clinically symptomatic?&...

5 Answers available

Papers discussed in this category

Cancer Treat Rev, 2022 Mar 12

Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management.

Pulmonology

Breast Cancer, Metastatic

Questions discussed in this category

Papers discussed in this category

Related Topics in Pulmonology